UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy.
Constraints
OAR
SABR
SBRT
normal tissue
stereotactic radiotherapy
Journal
Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
17
12
2021
revised:
21
01
2022
accepted:
14
02
2022
pubmed:
12
3
2022
medline:
13
4
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
The use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past decade, in part as the result of several UK clinical trials and a recent NHS England Commissioning through Evaluation programme. A UK SABR Consortium consensus for normal tissue constraints for SABR was published in 2017, based on the existing literature at the time. The published literature regarding SABR has increased in volume over the past 5 years and multiple UK centres are currently working to develop new SABR services. A review and update of the previous consensus is therefore appropriate and timely. It is hoped that this document will provide a useful resource to facilitate safe and consistent SABR practice.
Identifiants
pubmed: 35272913
pii: S0936-6555(22)00094-2
doi: 10.1016/j.clon.2022.02.010
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
288-300Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C19942/A2883
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C7224/A28724
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C33589/A28284
Pays : United Kingdom
Informations de copyright
Copyright © 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.